- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 -
The Real Good Food Company, Inc. (NASDAQ:RGF) reported fourth-quarter FY22 sales growth of 39.2% year-on-year to $35.65 million, missing the consensus…
2023 Outlook
For the full year 2023, the company expects:
Adjusted EBITDA of $3.9 billion to $4.1 billion
Includes approximately $0.5 billion unfavorable impact from fuel price and